Navigation Links
US Oncology Named to FORTUNE Magazine's Most Admired Companies List for Third Time
Date:3/12/2009

gy network were enrolled in clinical research trials across the nation. These services, as well as many others, are offered as an integrated solutions concept that serves the best interests of patients, practices and biotech/pharmaceutical partners.

About US Oncology

US Oncology, headquartered in the Houston area, works closely with physicians, payers, biotechnology, pharmaceutical and medical equipment manufacturers, to identify and deliver innovative services that enhance patient access to advanced cancer care. US Oncology supports one of the nation's foremost cancer treatment and research networks, accelerating the availability and use of evidence-based medicine and shared best practices.

US Oncology uses its expertise to support every aspect of the cancer care delivery system--from drug development to treatment and outcomes measurement--enabling the company to help increase the efficiency and safety of cancer care. According to the company's last quarterly earnings report, US Oncology is affiliated with 1,211 physicians operating in 456 locations, including 94 radiation oncology facilities in 39 states. For more information, visit the company's Web site, www.usoncology.com.


'/>"/>
SOURCE US Oncology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Campbell Alliance Brand Management Practice to Present at EyeForPharmas Oncology Summit USA and Oncology Market Access Europe Conference
2. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
3. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
4. Pharmatech 2.0: Introducing Pharmatech Oncology
5. Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting
6. Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug
7. Varian Medical Systems Introducing OncoView(TM) - an Oncology Specific Image Management and Storage Solution
8. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
9. Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International
10. Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials
11. First Coast Oncology to Offer Next Generation Proton Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 16, 2014  Vermillion, Inc. (NASDAQ: ... on gynecologic disease, today announced the next step in ... premier bio-analytics solutions provider with the naming of current ... and Chief Executive Officer, while current Chairman of the ... to serve as Chairman. These changes are effective January ...
(Date:12/17/2014)... LEXINGTON, Mass. , Dec. 17, 2014   ... a biopharmaceutical company developing therapeutic products for rare disorders, ... Healthcare Conference being held in San Francisco, ... , President and Chief Executive Officer, will present on ... p.m. EST).  The presentation will be webcast live and ...
(Date:12/15/2014)... NEW YORK , Dec. 15, 2014  GlassesOff ... Yuval Bar-Gil as an independent director of ... was founder of AeroScout and served as its CEO ... Decker in 2012, a $240 million transaction. Recognized as ... under Mr. Bar-Gil,s leadership, AeroScout provided Wi-Fi -based RFID ...
(Date:12/13/2014)... , Dec. 12, 2014 /CNW/ - MaRS and Virgin Unite ... that they have joined forces to support Canadian entrepreneurs tackling ... Virgin Group Founder was at the MaRS Centre to announce ... national impact venture fund. This fund has $1 million in ... Vancouver -based Mindset Social Innovation Foundation, founded by ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3
... -- China-Biotics, Inc.,(Nasdaq: CHBT ) ("China-Biotics", "the Company"), ... and,distribution of probiotics products, today announced its financial results for,the ... 2009. , , First Quarter 2010 Highlights, ... $15.4 million, -- Gross profit rose 34.5% ...
... , QUEBEC CITY, Aug. 17 /PRNewswire-FirstCall/ - AEterna Zentaris ... "Company"), a global biopharmaceutical company focused on endocrine therapy ... North American efficacy trial Z-033 and the safety trial ... endocrinology compound for urology, cetrorelix pamoate. As announced on ...
... the safety of their drinking water for granted, that ordinary ... Katzir of Tel Aviv University,s School of Physics and Astronomy. ... spillage, natural disaster or sabotage, the physicist has developed a ... community,s water supply in real time. Modifying special ...
Cached Biology Technology:China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 2China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 3China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 4China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 5China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 6China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 7China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 8China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 9China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 10China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 11AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 3AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 4AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 5AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 6AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 7Monitoring water through a snake's eyes 2Monitoring water through a snake's eyes 3
(Date:12/10/2014)... RALEIGH, N.C. , Dec. 9, 2014  Valencell, ... announced it is seeing a staggering demand from its ... demand, the Company revealed, is not solely coming from ... industries as well. "A wearable is only ... a result, accuracy is the ultimate driver in long-term ...
(Date:12/5/2014)... Dec. 4, 2014 Increased emphasis on ... in new testing and inspection technologies. The convergence ... to a range of innovative test solutions. This ... Generation Y, which is generally more inclined towards ... product development strategies of test equipment vendors will ...
(Date:11/21/2014)... -- According to a new market research ... Access Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), ... Geography - Global Forecasts to 2020", published by MarketsandMarkets, ... around $25 Billion in 2014 and is expected to ... of 8.69%. Browse 116 market data Tables ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... clumps of protein found within nerve cells are ... were first identified in the early 1900s by German ... in a protein called tau cause it to aggregate ... Normally, the tau protein is involved in the formation ...
... in the mainland United States known for its tropical smell now ... house ants - so called because they tend to invade houses ... to Hawaii. And, according to Purdue University entomologist Grzegorz Buczkowski, it ... "Odorous house ants in Hawaii are not like they are ...
... Mich. Discovering new treatments and battling dangerous infections ... targeting the genetic disorder cystic fibrosis with projects funded ... studies, with support from a $110,000 grant from Hunt ... Translational Sciences Institute, expand the relationship between the two ...
Cached Biology News:Chemical engineers help decipher mystery of neurofibrillary tangle formation in Alzheimer's brains 2Pesky ants found in Hawaii demonstrate invasive characteristics 24 projects target cystic fibrosis with Hunt for a Cure funds 2
... antibody raised against a partial ... Immunogen: SF3B2 (NP_006833, 592 ... recombinant protein with GST tag. ... NM_006842 ...
...
Mouse monoclonal antibody raised against a partial recombinant ZNF155. NCBI Entrez Gene ID = ZNF155...
Mouse polyclonal antibody raised against a partial recombinant COASY. NCBI Entrez Gene ID = 80347...
Biology Products: